Valuation Nile Pharmaceuticals and Chemical Industries Company
Stocks
NIPH
EGS38331C012
Pharmaceuticals
|
End-of-day quote
Egyptian Exchange
15/10/2026
|
5-day change | 1st Jan Change | ||
| 274.25 EGP | -0.99% |
|
-13.07% | +173.65% |
Company Valuation: Nile Pharmaceuticals and Chemical Industries Company
Data adjusted to current consolidation scope
| Fiscal Period: June | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|
| Market Cap 1 | 354.1 | 359 | 404.9 | 699.2 | 1,465 | 8,202 |
| Change | - | 1.4% | 12.77% | 72.69% | 109.54% | 459.75% |
| Enterprise Value (EV) 1 | 287.9 | 385.2 | 596 | 1,240 | 2,433 | 9,739 |
| Change | - | 33.83% | 54.7% | 108.1% | 96.15% | 300.34% |
| P/E | 5.5x | 4x | 3.4x | 7.75x | 11.7x | 32x |
| PBR | 0.95x | 0.83x | 0.85x | 1.49x | 1.97x | 7.66x |
| PEG | - | 0.1x | 0.1x | -0.3x | -0.2x | 1.4x |
| Capitalization / Revenue | 0.47x | 0.41x | 0.4x | 0.61x | 1.14x | 3.84x |
| EV / Revenue | 0.38x | 0.44x | 0.59x | 1.09x | 1.89x | 4.56x |
| EV / EBITDA | 2.67x | 2.76x | 3.39x | 7.97x | 7.9x | 16.2x |
| EV / EBIT | 3.01x | 3.07x | 3.66x | 8.64x | 8.71x | 18.2x |
| EV / FCF | 5.53x | -6.04x | -4.67x | -5.34x | -4.75x | -15.3x |
| FCF Yield | 18.1% | -16.6% | -21.4% | -18.7% | -21.1% | -6.52% |
| Dividend per Share 2 | 2 | 2.97 | 5 | 3.71 | 2 | - |
| Rate of return | 5.72% | 8.38% | 12.5% | 5.37% | 4.1% | - |
| EPS 2 | 6.363 | 8.856 | 11.77 | 8.911 | 4.191 | 5.127 |
| Distribution rate | 31.4% | 33.5% | 42.5% | 41.6% | 47.7% | - |
| Net sales 1 | 755.5 | 876.8 | 1,005 | 1,143 | 1,290 | 2,134 |
| EBITDA 1 | 107.7 | 139.4 | 175.9 | 155.5 | 307.9 | 602 |
| EBIT 1 | 95.6 | 125.4 | 162.8 | 143.5 | 279.3 | 535.2 |
| Net income 1 | 64.42 | 89.67 | 119.2 | 90.23 | 125.7 | 256.4 |
| Net Debt 1 | -66.22 | 26.21 | 191.1 | 540.9 | 967.4 | 1,537 |
| Reference price 2 | 34.97 | 35.46 | 39.99 | 69.06 | 48.84 | 164.03 |
| Nbr of stocks (in thousands) | 10,125 | 10,125 | 10,125 | 10,125 | 30,000 | 50,000 |
| Announcement Date | 9/14/21 A | 9/19/22 A | 9/20/23 A | 9/24/24 A | 9/9/25 A | 9/30/26 A |
1EGP in Million2EGP
Estimates
| P/E (Y) | EV / Sales (Y) | EV / EBITDA (Y) | Dividend Yield (Y) | Capi.($) | ||
|---|---|---|---|---|---|---|
| - | - | - | - | 257M | ||
| 35.96x | 12.96x | 27.14x | 0.55% | 1,120B | ||
| 37.4x | 6.3x | 17.74x | 2.09% | 616B | ||
| 36.43x | 8.36x | 17.24x | 2.43% | 504B | ||
| 20.46x | 4.99x | 12.38x | 2.64% | 367B | ||
| 106.52x | 5.95x | 25.12x | 2.33% | 360B | ||
| 21.18x | 5.54x | 13.63x | 2.88% | 288B | ||
| 21.7x | 4.38x | 12.55x | 2.01% | 258B | ||
| 27.46x | 7.06x | 12.64x | 2.33% | 234B | ||
| -45.63x | 6.99x | 27.07x | 2.11% | 194B | ||
| Average | 29.05x | 6.95x | 18.39x | 2.15% | 394.12B | |
| Weighted average by Cap. | 34.72x | 8.20x | 20.04x | 1.84% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
- Stock Market
- Stocks
- NIPH Stock
- Valuation Nile Pharmaceuticals and Chemical Industries Company
Select your edition
All financial news and data tailored to specific country editions
















